Update on psychotropic medications for cancer-related fatigue

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 10, 2007, Pages 1081-1091

  Breitbart, William ^a,b   Alici Evcimen, Yesne ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antidepressants; Cancer; Fatigue; Psychostimulants; Psychotropic medications; Wakefulness promoting agents

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NORTRIPTYLINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; BREAST CANCER; CANCER FATIGUE; CLINICAL EXAMINATION; DEPRESSION; DIET THERAPY; DISEASE SEVERITY; HUMAN; MELANOMA; PSYCHOSOCIAL CARE; SLEEP THERAPY;

EID: 37049031704     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0089     Document Type: Article

References (57)

1. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-360.
2. Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003;26:604-614.
3. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4-12.
4. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology 1998;12:369-377.
5. Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park) 2000;14:151-161.
6. Lawrence DP, Kupelnick B, Miller K, et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancel patients. J Natl Cancer Inst Monogr 2004;32:40-50.
7. Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist 2003;8(suppl 1):5-9.
8. Jacobsen PB, Hann DM, Azzarello LM, et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999;18:233-242.
9. Monga U, Kerrigan AJ, Thomby J, Monga TN. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat Oncol Investig 1999;7:178-185.
10. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18:743-753.
11. Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001;19:3385-3391.
12. Sadler IJ, Jacobsen PB, Booth-Jones M, et al. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 2002;23:406-416.
13. Lee KA, Hicks CJ, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res 1991;36:291-298.
14. Schag CC, Heinrich RL, Ganz PA. Karnofsky Performance Status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187-193.
15. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 1998;7:301-310.
16. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186-1196.
17. Piper B, Lindsey A, Dodd M, et al. Development of an instrument to measure the subjective dimension of fatigue. In: Funk SG, Tomquist EM, Champagne MT, et al., eds. Key Aspects of Comfort: Management of Pain, Fatigue and Nausea. New York: Springer; 1989:199-208.
18. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995;22:639-643.
19. Ahlberg K, Ekman T Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003;362:640-650.
20. Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 2002;12:424-428.
21. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006;24:2073-2078.
22. Reineke-Bracke H, Radbruch L, Elsner F. Treatment of fatigue: modafinil, methylphenidate, and goals of care. J Palliat Med 2006;9:1210-1214.
23. Kurzrock, R. The role of cytokines in cancer-related fatigue. Cancer 2001;92(suppl 6):1684-1688.
24. Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006;24:1852-1859.
25. Hussein MA. Research on thalidomide in solid tumors, hematologic malignancies, and supportive care. Oncology (Williston Park) 2000;14(suppl 12):9-15.
26. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005;89:243-249.
27. Savonije JH, van Groentngen CJ, Wormhoudt LW, Giaccone G. Early intervention with epoetin alta during platinum-based cbemothetapy: an analysis tit the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 2006;11:206-216.
28. Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr 2004;32:112-118.
29. Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: evidence-based interventions tor fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11:99-113.
30. Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001;18:187-192.
31. Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002;16:261-263.
32. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002;29:E85-90.
33. Bmera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate lor the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003;21:4439-4443.
34. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006;14:210-215.
35. Roth AJ, Nelson CJ, Rosenfeld B, et al. Randomized controlled trial testing methylphenidate as treatment for fatigue in men with prostate cancer [abstract]. Presented at 2006 ASCO Prostate Cancer Symposium; February 24-26, 2006; San Francisco, California. Abstract 275.
36. Lower E, Fleishman S, Cooper A, et al. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and "chemobrain" in adult cancer patients [abstract]. J Clin Oncol 2005;23(suppl 16):729s. Abstract 8000.
37. Morrow GM, Gillies LJ, Hickok JT, et al. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed [abstract]. J Clin Oncol 2005;23(suppl 16):732s. Abstract 8012.
38. Kaleita TA, Wellisch DK, Graham CA, et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors [abstract]. J Clin Oncol 2006;24(suppl 1):58s. Abstract 1503.
39. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsycho-pharmacology 2002;26:643-652.
40. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:4635-4641.
41. Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004;49:139-144.
42. Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 2006;15:259-267.
43. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 2003;64(suppl 11):14-18.
44. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001;161:411-420.
45. Holmes VF, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry 1989;50:5-8.
46. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000;61:436-440.
47. Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989;4:3-6.
48. Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer 2000;8:385-397.
49. Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006;2:130-136.
50. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006;11:93-102.
51. MacAllister WS, Krupp LB. Multiple sclerosis-related fatigue. Phys Med Rehabil Clin N Am 2005;16:483-502.
52. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-754.
53. Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998;2:74-78.
54. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage. 2006;32:551-559.
55. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003;26:1049-1054.
56. Pucci E, Branas P, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007;(1):CD002818.
57. Burks TF. New agents for the treatment of cancer-related fatigue. Cancer 2001;92(suppl 6):1714-1718.